Scarica l'app Stockscreener
5.25
1.32%
-0.07
Dopo l'orario di chiusura:
5.15
-0.10
-1.90%
Precedente Chiudi:
$5.32
Aprire:
$5.35
Volume 24 ore:
1.07M
Relative Volume:
1.04
Capitalizzazione di mercato:
$315.85M
Reddito:
-
Utile/perdita netta:
$-44.80M
Rapporto P/E:
-7.00
EPS:
-0.75
Flusso di cassa netto:
$-30.67M
1 W Prestazione:
+3.14%
1M Prestazione:
+27.12%
6M Prestazione:
-2.05%
1 anno Prestazione:
-12.86%
Intervallo 1D:
$5.155
$5.56
Intervallo di 1 settimana:
$5.15
$5.67
Portata 52W:
$1.14
$7.20
Aldeyra Therapeutics Inc Stock (ALDX) Company Profile
Nome
Aldeyra Therapeutics Inc
Settore
Industria
Telefono
781-761-4904
Indirizzo
131 HARTWELL AVENUE, LEXINGTON, MA
Compare ALDX vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ALDX
Aldeyra Therapeutics Inc
|
5.25 | 320.07M | 0 | -44.80M | -30.67M | -0.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Aldeyra Therapeutics Inc Stock (ALDX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-04-03 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2024-04-02 | Ripresa | H.C. Wainwright | Buy |
| 2022-04-27 | Ripresa | H.C. Wainwright | Buy |
| 2021-02-08 | Iniziato | H.C. Wainwright | Buy |
| 2020-12-16 | Iniziato | Berenberg | Buy |
| 2020-10-30 | Iniziato | Jefferies | Buy |
| 2020-10-16 | Iniziato | BTIG Research | Buy |
| 2020-09-22 | Iniziato | Alliance Global Partners | Buy |
| 2020-05-12 | Iniziato | Oppenheimer | Outperform |
| 2018-12-04 | Iniziato | Citigroup | Buy |
| 2018-09-26 | Reiterato | Cantor Fitzgerald | Overweight |
| 2018-09-13 | Iniziato | Janney | Buy |
| 2018-01-26 | Iniziato | Seaport Global Securities | Buy |
| 2016-09-26 | Iniziato | H.C. Wainwright | Buy |
| 2016-07-01 | Iniziato | Stifel | Buy |
| 2015-07-01 | Iniziato | Canaccord Genuity | Buy |
| 2015-03-25 | Iniziato | Chardan Capital Markets | Buy |
| 2015-03-20 | Reiterato | H.C. Wainwright | Buy |
| 2014-11-18 | Iniziato | H.C. Wainwright | Buy |
| 2014-06-19 | Iniziato | Aegis Capital | Buy |
Mostra tutto
Aldeyra Therapeutics Inc Borsa (ALDX) Ultime notizie
Published on: 2026-02-12 20:14:42 - baoquankhu1.vn
Aldeyra Therapeutics (NASDAQ:ALDX) Stock Price Passes Above 50 Day Moving AverageShould You Sell? - MarketBeat
Avoiding Lag: Real-Time Signals in (ALDX) Movement - Stock Traders Daily
Wall Street analysts predict a 65.75% upside in Aldeyra Therapeutics (ALDX): Here's what you should know - MSN
Wall Street Analysts Predict a 65.75% Upside in Aldeyra Therapeutics (ALDX): Here's What You Should Know - Finviz
Aldeyra Shares Climb on FDA Backing for PVRL Drug Trial Design - MSN
Are Medical Stocks Lagging Aldeyra Therapeutics (ALDX) This Year? - Yahoo Finance
PFG Investments LLC Reduces Stock Position in Aldeyra Therapeutics, Inc. $ALDX - MarketBeat
Aldeyra’s Dry Eye Drug Faces A Make-Or-Break FDA Call - Finimize
Discipline and Rules-Based Execution in ALDX Response - Stock Traders Daily
Aldeyra Therapeutics (NASDAQ:ALDX) Share Price Crosses Above Fifty Day Moving AverageHere's Why - MarketBeat
Earnings Recap: Is Aldeyra Therapeutics Inc exposed to political riskQuarterly Risk Review & Low Risk Profit Maximizing Plans - baoquankhu1.vn
Market Review: Does Aldeyra Therapeutics Inc have consistent dividend growthJuly 2025 Action & Low Volatility Stock Recommendations - baoquankhu1.vn
Will BOOT benefit from green energy policies2025 Fundamental Recap & Low Volatility Stock Recommendations - baoquankhu1.vn
How volatile is Aldeyra Therapeutics Inc. stockJuly 2025 Selloffs & Risk Adjusted Buy and Sell Alerts - mfd.ru
Aldeyra Therapeutics, Inc. (ALDX) Investigation: Bronstein, Gewir - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Is Investigating Aldeyra Thera - The National Law Review
Following a 4.3% decline over last year, recent gains may please Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) institutional owners - simplywall.st
Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) Short Interest Update - MarketBeat
Behavioral Patterns of ALDX and Institutional Flows - Stock Traders Daily
FDA Extends Review Timeline for Aldeyra's Dry Eye Drug Candidate () - aktiencheck.de
Support Test: Does Aldeyra Therapeutics Inc have a sustainable dividend2025 EndofYear Setup & Weekly High Potential Stock Alerts - baoquankhu1.vn
Aldeyra Therapeutics (ALDX) Leads in Earnings Momentum - GuruFocus
Head to Head Review: Scienture (NASDAQ:SCNX) & Aldeyra Therapeutics (NASDAQ:ALDX) - Defense World
Analysis Recap: Is Aldeyra Therapeutics Inc stock trending bullish2025 Momentum Check & Community Trade Idea Sharing Platform - baoquankhu1.vn
Insider Buy: Does National Energy Services Reunited Corp Equity Warrant stock reflect fundamentals2025 Market Overview & Risk Controlled Swing Alerts - baoquankhu1.vn
Trend Review: Is Envirotech Vehicles Inc in accumulation or distribution phaseJobs Report & Consistent Profit Trade Alerts - baoquankhu1.vn
Will Betterware de Mxico SAPI de CV benefit from green energy policiesMarket Movers & Real-Time Stock Entry Alerts - baoquankhu1.vn
Sell Signal: What is the dividend yield of Trailblazer Merger Corporation I Equity RightJuly 2025 Update & Advanced Swing Trade Entry Alerts - baoquankhu1.vn
Aldeyra drops as FDA delays review of marketing application for lead drug - MSN
Will Aldeyra Therapeutics Inc. stock maintain momentum in 2025Weekly Profit Report & Risk Controlled Daily Trade Plans - Улправда
Market Trends: Will Aldeyra Therapeutics Inc. stock maintain momentum in 2025Portfolio Risk Report & Fast Gain Stock Tips - Bộ Nội Vụ
Aldeyra Therapeutics (NASDAQ:ALDX) Stock Passes Below 50 Day Moving AverageTime to Sell? - MarketBeat
Can Aldeyra Therapeutics Inc. stock rebound after recent weaknessDay Trade & Daily Entry Point Trade Alerts - Улправда
Why Aldeyra Therapeutics Inc. stock attracts high net worth investors2025 Big Picture & Weekly Momentum Stock Picks - Улправда
Growth Value: Why Aldeyra Therapeutics Inc. stock attracts high net worth investorsEarnings Risk Summary & Detailed Earnings Play Strategies - Улправда
News | postregister.comAldeyra Therapeutics, Inc.Common Stock (Nasdaq:ALDX) Detailed Stock Data - FinancialContent
(ALDX) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Aldeyra Therapeutics announces chief development officer resignation - MSN
Analysts Offer Insights on Healthcare Companies: Aldeyra Therapeutics (ALDX) and Foghorn Therapeutics (FHTX) - The Globe and Mail
What to keep an eye on in 2026 - Eyes On Eyecare
Aldeyra Therapeutics Chief Development Officer Stephen Machatha to Resign - marketscreener.com
Aldeyra Therapeutics (NASDAQ:ALDX) Shares Cross Above Fifty Day Moving AverageTime to Sell? - MarketBeat
Aldeyra Therapeutics Announces Chief Development Officer Resignation - The Globe and Mail
Aldeyra Therapeutics chief development officer to step down by March 2026 - Investing.com Nigeria
Aldeyra Therapeutics chief development officer to step down by March 2026 By Investing.com - Investing.com India
Aldeyra Therapeutics Announces Resignation of Chief Development Officer - TradingView — Track All Markets
Aldeyra Therapeutics: Reproxalap’s March 2026 FDA Decision Is The Defining Catalyst - Seeking Alpha
Why is Aldeyra Therapeutics stock surging after FDA delayed its dry eye drug decision? - MSN
Aldeyra Therapeutics Inc Azioni (ALDX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.24%
0.19%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):